EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity

Meredith M Hoog iD, Hong Kan, Kristen A Deger, Sonja Sorensen, Lisa M Neff iD, Jay Patrick Bae, Emily Ruth Hankosky, Madhumita Murphy, Donna Mojdami, Ivan Houisse, Mack S Harris

Obesity · 2025-07 · 33 (7) · 1297-1308

DOI: 10.1002/oby.24310 ↗

At a glance

Journal article in Obesity, published online on 2025-06-13. Written by Meredith M Hoog and 10 co-authors. Institution: Eli Lilly and Company, Indianapolis, Indiana, USA. Major MEDLINE topics: Obesity, Overweight. Cited 9 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: Eli Lilly and Company.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Our objective was to model the potential cost‐effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.

Methods

An individual‐level discrete event simulation was implemented in Microsoft Excel linking short‐term outcomes from the SURMOUNT‐1 trial to key obesity‐related complications to estimate costs and health benefits of tirzepatide (5‐mg, 10‐mg, or 15‐mg doses) and LSM over a lifetime time horizon. Treatment‐related changes in cardiometabolic factors were modeled using data from SURMOUNT‐1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.

Results

Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality‐adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost‐effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.

Conclusions

The model predicted that all doses of tirzepatide represent cost‐effective alternatives to LSM for management of overweight and obesity at a willingness‐to‐pay threshold of $150,000 per QALY.

Subjects

MeSH terms (MEDLINE)

ObesityOverweightHumansCost-Benefit AnalysisQuality-Adjusted Life YearsFemaleMaleMiddle AgedAdultLife StyleTirzepatide

Substances

Tirzepatide

Authors and institutions

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Evidera Inc., Wilmington, North Carolina, USA.
  • Evidera, Budapest, Hungary.

ORCID profiles: Meredith M Hoog, Lisa M Neff

Funding

  • Eli Lilly and Company

Cite

APA

Hoog, M. M., Kan, H., Deger, K. A., Sorensen, S., Neff, L. M., Bae, J. P., Hankosky, E. R., Murphy, M., Mojdami, D., Houisse, I., & Harris, M. S. (2025). Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity, 33(7), 1297-1308. https://doi.org/10.1002/oby.24310

Vancouver

Hoog MM, Kan H, Deger KA, Sorensen S, Neff LM, Bae JP, et al. Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. Obesity. 2025;33(7):1297-1308. doi:10.1002/oby.24310

BibTeX
@article{Hoog2025,
  author = {Hoog, Meredith M and Kan, Hong and Deger, Kristen A and Sorensen, Sonja and Neff, Lisa M and Bae, Jay Patrick and Hankosky, Emily Ruth and Murphy, Madhumita and Mojdami, Donna and Houisse, Ivan and Harris, Mack S},
  title = {Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {7},
  pages = {1297--1308},
  doi = {10.1002/oby.24310}
}
Start for free →